CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
Neumifil +1 moredrug
Likely dose
Neumifil intranasal spray (specific dose not stated in protocol)AI-extracted
Key inclusion· 4
  • ✓Age 18-55 years old
  • ✓Body weight ≥50 kg and BMI 18-35 kg/m²
  • ✓Good general health with no clinically significant medical conditions or test abnormalities that interfere with safety
  • ✓Serosuitable for the challenge virus (appropriate serostatus for influenza challenge)
Key exclusion· 15
  • ✕Upper or lower respiratory tract infection within 4 weeks prior to first study visit
  • ✕Clinically significant or active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic, urological, renal, neurological, or psychiatric disease; includes history of depression or anxiety
  • ✕Smoking history of ≥10 pack-years at any time
  • ✕Pregnancy or breastfeeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05507567
NCT05507567Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants

Pneumagen Ltd.·interventional·Posted Aug 19, 2022·Updated Oct 28, 2024

In Brief

A Phase 2 clinical trial evaluating Neumifil and Placebo for Influenza Viral Infections. Completed, enrolled 104 participants across 1 site.

Detailed Summary

Study to assess the efficacy and safety of a multiple dose regimen and a single dose regimen of intranasal Neumifil, administered prior to challenge with Influenza virus in healthy adult participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Viral Infections
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedAug 19, 2022
Enrollment StartAug 12, 2022
Primary CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.9 years ago

Interventions

Neumifildrug

Liquid for intranasal spray administration

Placebodrug

Liquid for intranasal spray administration